Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Drug Alcohol Depend ; 152: 164-9, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25935736

ABSTRACT

OBJECTIVE: Medication assisted treatment with buprenorphine/naloxone (Bup/Nx), including prescribing and dispensing practices of general practitioners (GPs) in Malaysia and their patients' experiences with this treatment have not been systematically examined. The current study surveyed GPs providing Bup/Nx treatment and patients receiving office-based Bup/Nx treatment in Malaysia. METHODS: Two cross-sectional surveys of GPs (N=115) providing outpatient Bup/Nx maintenance treatment and of patients (N=253) currently receiving Bup/Nx treatment throughout peninsular Malaysia. RESULTS: Physicians prescribed Bup/Nx dosages in the range of 2-4mg daily for 70% of patients and conducted urine testing in the past month on approximately 16% of their patients. In the patient survey, 79% reported taking daily Bup/Nx doses of 2mg or less; 82% reported that no urine toxicology testing had been conducted on them in the past month, 36% had an opiate positive urine test at the time of the survey, 43% reported illicit opiate use, 15% reported injection of heroin and 22% reported injection of Bup/Nx in the past month. CONCLUSION: Low daily Bup/Nx doses, lack of behavioral monitoring or counseling, and high rates of continued drug use, including injection of drugs and medications during Bup/Nx treatment in Malaysia, indicate continuing problems with implementation and less than optimal treatment effectiveness. High cost of Bup/Nx in Malaysia may deter patients from seeking treatment and contribute to taking low Bup/Nx dosages. Improved training of physicians and establishing standards for Bup/Nx dosing, routine toxicology testing, and counseling may be needed to improve care and treatment response.


Subject(s)
Attitude of Health Personnel , Buprenorphine, Naloxone Drug Combination/therapeutic use , Opioid-Related Disorders/drug therapy , Patient Satisfaction/statistics & numerical data , Adult , Cross-Sectional Studies , Female , Humans , Malaysia , Male , Narcotic Antagonists/therapeutic use , Opiate Substitution Treatment/methods , Surveys and Questionnaires
2.
Drug Alcohol Depend ; 115(3): 237-9, 2011 Jun 01.
Article in English | MEDLINE | ID: mdl-21159452

ABSTRACT

This pilot clinical trial evaluated whether the efficacy of methadone maintenance treatment (MMT) provided with limited psychosocial services is improved by the addition of manual-guided behavioral drug and HIV risk reduction counseling (BDRC). Heroin dependent individuals (n=37) enrolling in two MMT clinics in Wuhan, China, received standard MMT services, consisting of daily medication at the clinics and infrequent additional services on demand, and were randomly assigned to MMT only (n=17) or MMT with weekly individual BDRC (n=20) for 3 months. Participants were followed for six months from the time of enrollment (3 months active counseling phase and 3 months follow-up while treated with standard MMT). Primary outcome measures included reductions of HIV risk behaviors and illicit opiate use and treatment retention. Participants were 81% male; mean (SD) age 36.7 (7.2) years; there were no significant baseline differences between the two groups. Participants in MMT+BDRC achieved both greater reductions of HIV risk behaviors (p<0.01), as indicated by the scores on a short version of the AIDS Risk Inventory, and of illicit opiate use, as indicated by the proportions of opiate negative test results during the active phase of the study and the follow-up (p<0.001). 83.3% in the MMT+BDRC group and 76.2% in the standard MMT group were still actively participating in MMT at 6 months. Manual-guided behavioral drug and HIV risk reduction counseling is feasible to deliver by the trained MMT nursing personnel and appears to be a promising approach for improving the efficacy of standard MMT services in China.


Subject(s)
Counseling/methods , HIV Infections/prevention & control , Methadone/therapeutic use , Narcotics/therapeutic use , Opiate Substitution Treatment/methods , Substance-Related Disorders/prevention & control , Adult , China , Female , HIV Infections/psychology , HIV Seropositivity/metabolism , Heroin Dependence/drug therapy , Heroin Dependence/rehabilitation , Humans , Male , Methadone/administration & dosage , Narcotics/administration & dosage , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/rehabilitation , Pilot Projects , Risk Reduction Behavior , Risk-Taking , Substance-Related Disorders/psychology , Temperance/psychology
3.
Drug Alcohol Depend ; 111(1-2): 44-9, 2010 Sep 01.
Article in English | MEDLINE | ID: mdl-20478668

ABSTRACT

BACKGROUND: Buprenorphine maintenance is efficacious for treating opioid dependence, but problems with diversion and misuse of buprenorphine (BUP) may limit its acceptability and dissemination. The buprenorphine/naloxone combination tablet (BNX) was developed to reduce potential problems with diversion and abuse. This paper provides data regarding the characteristics of BUP injection drug users in Malaysia and preliminary data regarding the impact of withdrawing BUP and introducing BNX. BUP was introduced in 2002 and subsequently withdrawn from the Malaysian market in 2006. BNX was introduced in 2007. METHODS: A two wave survey of BUP IDUs was conducted shortly prior to BUP withdrawal from the Malaysian market (n=276) and six months after BNX was introduced (n=204). Six focus groups with BUP and/or BNX IDUs were also conducted shortly before the second wave. RESULTS: In addition to current BUP or BNX IDU, 96% of first wave participants and 97% second wave participants reported lifetime heroin IDU preceding the onset of their BUP/BNX IDU. Additionally, 58% of first and 64% of second wave survey participants reported current heroin IDU. Benzodiazepine abuse, often injected with BUP, was reported in both the surveys. Focus group participants reported that BNX was not as desirable as BUP, nonetheless, the results of the second wave survey suggest a continuing widespread BNX IDU, at least in Kuala Lumpur. CONCLUSIONS: In Malaysia, BUP and BNX IDU occur among heroin IDUs. The introduction of BNX and withdrawal of BUP may have helped to reduce, but did not eliminate the problems with diversion and abuse.


Subject(s)
Buprenorphine/administration & dosage , Naloxone/administration & dosage , Opioid-Related Disorders/epidemiology , Substance Abuse, Intravenous/epidemiology , Adult , Female , Health Behavior , Health Surveys , Heroin/administration & dosage , Humans , Injections, Intravenous , Malaysia/epidemiology , Male , Middle Aged , Narcotic Antagonists/administration & dosage , Needle Sharing/statistics & numerical data , Patient Selection , Prevalence , Risk Management , Risk-Taking
5.
Drug Alcohol Depend ; 94(1-3): 281-4, 2008 Apr 01.
Article in English | MEDLINE | ID: mdl-18164145

ABSTRACT

This pilot randomized clinical trial evaluated whether the efficacy of office-based buprenorphine maintenance treatment (BMT), provided with limited counseling or oversight of medication adherence is improved by the addition of individual drug counseling and abstinence-contingent take-home doses of buprenorphine. After a 2-week buprenorphine and stabilization period, heroin dependent individuals (n=24) in Muar, Malaysia were randomly assigned to Standard Services BMT (physician administered advice and support, and weekly, non-contingent medication pick-up) or Enhanced Services (nurse-delivered manual-guided behavioral drug and HIV risk reduction counseling (BDRC) and abstinence-contingent take-home buprenorphine (ACB), 7 day supply maximum). Outcomes included retention, proportion of opioid-negative urine tests, self-reported drug use, and self-reported HIV risk behaviors. 12/12 (100%) of Enhanced Services and 11/12 (92%) of Standard Services participants completed the entire protocol. The proportion of opioid-negative urine tests increased significantly over time for both groups (p<0.001), and the reductions were significantly greater in the Enhanced Services group (p<0.05); Enhanced Services group achieved higher overall proportions of opiate negative urine toxicology tests (87% vs. 69%, p=0.04) and longer periods of consecutive abstinence from opiates (10.3 weeks vs. 7.8 weeks, p=0.154). Both groups significantly reduced HIV risk behaviors during treatment (p<0.05), but the difference between Enhanced and Standard Services (26% vs. 17% reductions from the baseline levels, respectively) was not statistically significant (p=0.9). Manual-guided behavioral drug and HIV risk reduction counseling and abstinence-contingent take-home buprenorphine appear promising for adding to the efficacy of office-based BMT provided with limited drug counseling and medication oversight.


Subject(s)
Buprenorphine/therapeutic use , Counseling , HIV Infections/epidemiology , Heroin Dependence/epidemiology , Heroin Dependence/rehabilitation , Home Care Services , Narcotics/therapeutic use , Risk Reduction Behavior , Adolescent , Adult , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , Male , Middle Aged , Patient Acceptance of Health Care/statistics & numerical data , Pilot Projects
6.
JAMA ; 286(14): 1724-31, 2001 Oct 10.
Article in English | MEDLINE | ID: mdl-11594897

ABSTRACT

CONTEXT: Methadone maintenance is an effective treatment for opioid dependence, yet its use is restricted to federally licensed narcotic treatment programs (NTPs). Office-based care of stabilized methadone maintenance patients is a promising alternative but no data are available from controlled trials regarding this type of program. OBJECTIVE: To determine the feasibility and efficacy of office-based methadone maintenance by primary care physicians vs in an NTP for stable opioid-dependent patients. DESIGN: Six-month, randomized controlled open clinical trial conducted February 1999-March 2000. SETTING: Offices of 6 primary care internists and an NTP. PATIENTS: Forty-seven opioid-dependent patients who had been receiving methadone maintenance therapy in an NTP without evidence of illicit drug use for 1 year and without significant untreated psychiatric comorbidity were randomized; 1 patient refused to participate after treatment assignment to NTP. INTERVENTIONS: Patients were randomly assigned to receive office-based methadone maintenance from primary care physicians, who received specialized training in the care of opioid-dependent patients (n = 22), or usual care at an NTP (n = 24). MAIN OUTCOME MEASURES: Illicit drug use, clinical instability (persistent drug use), patient and clinician satisfaction, functional status, and use of health, legal, and social services, compared between the 2 groups. RESULTS: Eleven of 22 (50%; 95% confidence interval [CI], 29%-71%) patients in office-based care compared with 9 of 24 (38%; 95% CI, 21%-57%) of NTP patients had a self-report or urine toxicology test result indicating illicit opiate use (P =.39). Hair toxicology testing detected an additional 2 patients in each treatment group with evidence of illicit drug use, but this did not change the overall findings. Ongoing illicit drug use meeting criteria for clinical instability occurred in 4 of 22 (18%; 95% CI, 7%-39%) patients in office-based care compared with 5 of 24 (21%; 95% CI, 9%-41%) NTP patients (P =.82). Sixteen of the 22 (73%; 95% CI, 54%-92%) office-based patients compared with 3 of the 24 (13%; 95% CI, 0%-26%) NTP patients thought the quality of care was excellent (P =.001). There were no differences over time within or between groups in functional status or use of health, legal, or social services. CONCLUSIONS: Our results support the feasibility and efficacy of transferring stable opioid-dependent patients receiving methadone maintenance to primary care physicians' offices for continuing treatment and suggest guidelines for identifying patients and clinical monitoring.


Subject(s)
Family Practice , Methadone/therapeutic use , Opioid-Related Disorders/rehabilitation , Substance Abuse Treatment Centers , Adult , Feasibility Studies , Female , Humans , Male , Middle Aged , Outcome and Process Assessment, Health Care , Patient Satisfaction , United States
7.
Pain Med ; 2(4): 298-308, 2001 Dec.
Article in English | MEDLINE | ID: mdl-15102234

ABSTRACT

OBJECTIVE: This study presents information on the development of an interactive computer-based rating method of quality of life that assesses the multidimensional impact of chronic pain on the individual. METHOD: A software program assessing 20 categories of quality of life was created and administered to 103 chronic pain patients. Comparison data were obtained from 103 matched healthy controls. RESULTS: High variability was found among pain patients in their ratings of quality of life, and pain patients rated all categories lower than controls. Three groups emerged from a cluster analysis of the data reflecting high, mixed, and low ratings of satisfaction with quality of life. CONCLUSIONS: The rating method was convenient, was easy for the patient to understand, and took very little time to administer. Further investigation of the validity and reliability of this tool is needed.

8.
Biol Psychiatry ; 47(12): 1072-9, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10862807

ABSTRACT

BACKGROUND: Buprenorphine is a promising alternative to methadone or levo-acetyl alpha methadol for opioid agonist maintenance treatment, and thrice-weekly dosing would facilitate its use for this purpose. METHODS: After a 3-day induction, opioid-dependent patients (n = 92) were randomly assigned to daily clinic attendance and 12-weeks maintenance treatment with sublingual buprenorphine administered double blind either daily (n = 45; 16 mg/70 kg) or thrice weekly (n = 47; 34 mg/70 kg on Fridays and Sundays and 44 mg/70 kg on Tuesdays). Outcome measures include retention, results of 3x/week urine toxicology tests, and weekly self-reported illicit drug use. RESULTS: There were no significant differences at baseline in important social, demographic, and drug-use features. Retention was 71% in the daily and 77% in the 3x/week conditions. The proportion of opioid-positive urine tests decreased significantly from baseline in both groups and averaged 57% (daily) and 58% in 3x/week. There were no significant differences between groups in self-reported number of bags of heroin used for any day of the week, including Thursdays (48-72 hours following the last buprenorphine dose for subjects in the 3x/week condition), or in medication compliance (92%, 91%) and counseling attendance (82%, 82%). CONCLUSIONS: At an equivalent weekly dose of 112 mg/70 kg, thrice-weekly and daily sublingual buprenorphine appear comparable in efficacy with regard to retention and reductions in illicit opioid and other drug use. These findings support the potential for utilizing thrice-weekly buprenorphine dosing in novel settings.


Subject(s)
Buprenorphine/therapeutic use , Narcotic Antagonists/therapeutic use , Opioid-Related Disorders/rehabilitation , Adult , Buprenorphine/administration & dosage , Buprenorphine/blood , Cocaine-Related Disorders/psychology , Cocaine-Related Disorders/rehabilitation , Double-Blind Method , Female , Heroin Dependence/psychology , Heroin Dependence/rehabilitation , Humans , Male , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/blood , Opioid-Related Disorders/psychology , Psychiatric Status Rating Scales
9.
Biol Psychiatry ; 47(12): 1080-6, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10862808

ABSTRACT

BACKGROUND: We examined the effects of disulfiram versus placebo on cocaine dependence in buprenorphine-maintained subjects. METHODS: Opioid and cocaine dependent subjects (n = 20) were induced onto buprenorphine maintenance, then randomized to disulfiram (250 mg q.d. ; n = 11) or placebo (n = 9) treatment for 12 weeks. RESULTS: Groups were comparable at baseline on demographic measures and on baseline measures of drug-use severity. Fifteen subjects completed the study, including 8 subjects randomized to disulfiram (72.7%) and 7 subjects randomized to placebo (77.8%). The total number of weeks abstinent from cocaine was significantly greater on disulfiram versus placebo (mean +/- SD: 7.8 +/- 2.6 vs. 3.3 +/- 0.5, p <.05) and the number of days to achieving 3 weeks (24.6 +/- 15.1 vs. 57.8 +/- 7.7, p <.01) of continuous cocaine abstinence was significantly lower in disulfiram compared with placebo. The number of cocaine-negative urine tests during the trial were also higher on disulfiram (14.7) than on placebo (8.6); furthermore, subjects in the disulfiram group achieved consistently higher rates of cocaine-negative urine tests in each 3-week interval and the increase over time was faster in the disulfiram compared with placebo. CONCLUSIONS: This preliminary study suggests the potential efficacy of disulfiram versus placebo for treatment of cocaine dependence in buprenorphine-maintained patients.


Subject(s)
Alcohol Deterrents/therapeutic use , Buprenorphine/therapeutic use , Cocaine-Related Disorders/rehabilitation , Disulfiram/therapeutic use , Narcotic Antagonists/therapeutic use , Adult , Alcohol Deterrents/adverse effects , Chi-Square Distribution , Cocaine-Related Disorders/psychology , Disulfiram/adverse effects , Female , Heroin Dependence/psychology , Heroin Dependence/rehabilitation , Humans , Male , Substance Abuse Detection , Time Factors
10.
J Subst Abuse Treat ; 18(3): 255-61, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10742639

ABSTRACT

We compared outcomes for agonist-maintained patients with combined opioid and cocaine dependence who were treated in an earlier clinical trial with group drug counseling (DC; n = 57) or in a current trial with the Community Reinforcement Approach (CRA; n = 60). The association between engagement in nondrug-related activities and abstinence was also evaluated. There were no significant differences between the treatments in retention or drug use. The total number of hours and average hours per week engaged in nondrug-related activities was significantly higher for CRA-treated patients who achieved abstinence from opioids, cocaine, or both combined than for those who never achieved abstinence. Although CRA was not more effective overall than DC, the finding that engagement in reinforcing community activities unrelated to drug use (e.g., planned pleasurable events or parenting activities) was associated with abstinence suggests that the planning and reinforcement of specific nondrug-related social, vocational, and recreational activities is a crucial component of CRA.


Subject(s)
Buprenorphine/therapeutic use , Cocaine-Related Disorders/rehabilitation , Community Networks/statistics & numerical data , Counseling , Methadone/therapeutic use , Narcotics/therapeutic use , Opioid-Related Disorders/rehabilitation , Adult , Clinical Trials as Topic , Cocaine-Related Disorders/complications , Female , Humans , Male , Opioid-Related Disorders/complications , Recurrence , Social Support , Socioenvironmental Therapy/methods , Temperance , Treatment Outcome , United States
11.
Drug Alcohol Depend ; 55(1-2): 157-63, 1999 Jun 01.
Article in English | MEDLINE | ID: mdl-10402160

ABSTRACT

BACKGROUND: This study evaluated plasma buprenorphine concentrations 24-72 h following sublingual administration of a dose of buprenorphine solution, ranging from 16 mg/70 kg to 44 mg/70 kg, administered on a daily or thrice-weekly schedule. Additionally, this study evaluated the effects of different thrice-weekly buprenorphine dose schedules on opiate use and withdrawal symptoms. METHODS: Opiate dependent subjects (n = 10) were maintained in an outpatient clinic for two 3-week periods at each of three thrice-weekly buprenorphine dose schedules (providing a weekly total buprenorphine dose of 64, 84 and 112 mg) and for 1 week of a daily buprenorphine dose of 16 mg/70 kg. Plasma samples were obtained 24, 48 and 72 h following administration of buprenorphine. Urine samples were also collected and opiate withdrawal symptoms, agonist effects and the use of heroin, cocaine, alcohol and other drugs, were assessed. RESULTS: Plasma levels showed a wide range of intra- and inter-subject variability. Nonetheless, higher doses of buprenorphine resulted in higher plasma concentrations at each time point and plasma concentration decreased with time. There were no significant differences in heroin use across dosing. Rates of withdrawal symptoms were low and did not differ across dosing schedules. CONCLUSIONS: In the two highest dose schedules, plasma levels 72 h following the administration of the highest dose and at 48 h after the lower dose, were comparable to plasma concentrations at 24 h following daily administration of 16 mg/70 kg of buprenorphine.


Subject(s)
Buprenorphine/blood , Narcotics/blood , Administration, Sublingual , Buprenorphine/therapeutic use , Cocaine/blood , Dose-Response Relationship, Drug , Double-Blind Method , Ethanol/blood , Female , Heroin/blood , Humans , Male , Narcotics/therapeutic use , Opioid-Related Disorders/blood , Opioid-Related Disorders/rehabilitation , Opioid-Related Disorders/urine , Substance Withdrawal Syndrome/blood , Substance Withdrawal Syndrome/diagnosis , Substance Withdrawal Syndrome/urine , Time Factors
12.
J Addict Dis ; 17(4): 49-59, 1998.
Article in English | MEDLINE | ID: mdl-9848031

ABSTRACT

Based on the review of existing instruments and analysis of problems encountered in clinical and research practice with one of the most commonly used assessment instruments, the RAB, this paper proposes a number of solutions aimed at improving validity, and efficiency of assessment of HIV risk in drug abusing populations. Briefly, five domains of assessment are discussed: intravenous drug use, high-risk sexual behaviors, knowledge of HIV transmission and methods of prevention, psychological aspects of behavioral change, and epidemiological factors of HIV transmission. The paper discusses also changes in format, scope, and context, as well as scoring procedures that may improve discriminability and sensitivity to detect change of a comprehensive HIV risk assessment instrument. Finally, a process of developing an HIV risk assessment instrument, the ARI-I, which is based on the proposed recommendations and which incorporates methodological improvements discussed in the paper is briefly described.


Subject(s)
HIV Infections/psychology , Risk Assessment/methods , Risk-Taking , Surveys and Questionnaires/standards , HIV Infections/transmission , Humans , Predictive Value of Tests , Reproducibility of Results , Sensitivity and Specificity , Substance-Related Disorders/complications , Substance-Related Disorders/psychology
13.
J Exp Psychol Gen ; 122(2): 195-206, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8315400

ABSTRACT

In 5 experiments using a priming methodology, the role of contextual factors on Ss' performance in a word-recognition task was investigated. Ss read short stories, and then their recognition of words from the stories was tested. Effects of contextual factors on Ss' performance were examined by manipulating the context of the stories' presentation and by designing the experimental materials to weaken the effects of semantic relations between primes and targets, thereby enhancing Ss' opportunity to use contextual relations between the words. The overall results of all 5 experiments indicate that context influences the priming effect of close semantic relations. They can be interpreted as supporting cue-retrieval models of priming mechanisms.


Subject(s)
Attention , Mental Recall , Paired-Associate Learning , Adult , Female , Humans , Inhibition, Psychological , Male , Reaction Time , Semantics
SELECTION OF CITATIONS
SEARCH DETAIL
...